Clinical Trials Directory

We are doing this study to compare 2 different surgeries for epithelial ovarian cancer. We want to know if an investigational surgical procedure called minimally invasive surgery can offer better results than the standard surgery, which is called laparotomy. We hope to find out if one procedure or the other is preferable when it comes to preventing cancer from returning and giving patients a better quality of life after their surgery.

We are doing this study to find out if a small dose (0.5 mg) of a drug called colchicine (the study drug) is beneficial for people with peripheral artery disease (PAD). We want to know if it has the potential to lower the risk of heart attack, stroke, and corrective leg surgeries for people who have PAD. The study drug is FDA-approved for the treatment of some inflammatory conditions (e.g., gout), but it is not approved for the treatment of PAD.

We are doing this study to support vaccine development by studying blood cells of the immune system.

We are doing this study to test different combinations of ultrasound stimulation that might help restore arm strength for people dealing with arm weakness after a stroke. We want to find out which combination appears to have the most positive benefit for enhancing motor function and boosting brain activity.

We are doing this study to learn more about why the right side of the heart doesn't work well in certain heart conditions. We're using heart tissue samples from people with specific heart problems to help us make these important discoveries.

We are doing this study to collect blood and cerebrospinal fluid samples from patients who have breast cancer that has spread to the brain and/or spinal cord. We hope that by analyzing these samples, we can find out how effective different cancer medications are at treating metastases to the leptomeninges (tissue that surrounds the brain and spinal cord). We also want to do genetic testing on these samples to look for cancer mutations that can give us clues about how people might respond to different therapies or which therapies are most likely to be helpful.

We are doing this study to find out if an experimental technology is a safe and effective way to administer treatment for relapsed and/or refractory multiple myeloma (RRMM). We want to know if giving the drug isatuximab as an injection under the skin works as well as giving this same drug as an intravenous (IV) infusion. The drug combination of isatuximab, carfilzomib, and dexamethasone is approved for the treatment of RRMM, but the current standard of care is to give isatuximab through an IV.

We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.